NEW YORK, September 30, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on the following
equities: ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), VIVUS,
Inc. (NASDAQ: VVUS), Keryx Biopharmaceuticals, Inc.
(NASDAQ: KERX), MannKind Corporation (NASDAQ: MNKD), and
Ovascience Inc. (NASDAQ: OVAS). On Tuesday, September 29, 2015, Nasdaq ended at
4,517.32, down 0.59%, Dow Jones advanced 0.30% to finish the day at
16,049.13, and the S&P closed at 1,884.09, up 0.12%. Register
for your complimentary reports at the links given below.
ZIOPHARM Oncology Inc.
ZIOPHARM Oncology Inc.'s stock edged lower by 3.07% to close
Tuesday's session at USD 8.85. The
company's shares oscillated between USD 8.67
and USD 9.94. The stock recorded a trading volume of 4.75
million shares, which was above its 50-day daily average volume of
3.49 million shares. Over the last three days ZIOPHARM Oncology
Inc.'s shares have declined by 30.42% and in the past one week the
stock has moved down 29.20%. On a compounded total return basis,
the company stock has shown a negative return of 1.56% in the past
one month. The stock is trading at a price to book ratio of 10.48
and price to sales ratio of 763.38. Sign up and read the free notes
on ZIOP at: http://www.aciassociation.com/ZIOP.pdf
Vivus Inc.
The stock of Vivus Inc. lost 4.68% to close Tuesday's session at
USD 1.63. The shares of the company
moved in the range of USD 1.60 and
USD 1.75. A trading volume of 4.35
million shares was recorded, which was greater than its 150-day
daily average volume of 2.22 million shares. Over the last five
days, Vivus Inc.'s shares have declined by 1.81% while in the past
one month the stock has gained a momentum of 46.85%. The company
has returned 41.74% in the past one month, on a compounded total
return basis. The stock is trading at a price to book ratio of 8.19
and price to sales ratio of 1.53. Register for free on ACI
Association and access the latest research on VVUS at:
http://www.aciassociation.com/VVUS.pdf
Keryx Biopharmaceuticals Inc.
Keryx Biopharmaceuticals Inc.'s stock increased by 4.89% to
close Tuesday's session at USD 3.54.
The company's shares fluctuated in the range of USD 3.40 and USD
3.92. A total of 4.02 million shares exchanged hands, which
surpassed its 50-day daily average volume of 2.08 million shares.
Over the last three days Keryx Biopharmaceuticals Inc.'s shares
have declined by 11.06% and in the past one week the stock has
moved down 9.46%. Furthermore, over the last three months the stock
has lost 64.53%. The stock is at a price to book ratio of 2.53 and
price to sales ratio of 82.48. The complete research on KERX is
available for free at: http://www.aciassociation.com/KERX.pdf
Mannkind Corp.
Mannkind Corp's stock added 0.97% to close Tuesday's session at
USD 3.12. The company's shares
oscillated between USD 3.03 and USD
3.32. The stock recorded a trading volume of 3.90 million
shares, which was below its 50-day daily average volume of 5.14
million shares. Over the last five days Mannkind Corp's shares have
declined by 3.70% and in the past one month the stock has lost
20.20%. In addition, over the last three months the stock has lost
45.17% and year to date the shares have shed 40.17%. The stock is
trading at a price to cash flow ratio of 17.86. Free in-depth
research on MNKD is available at:
http://www.aciassociation.com/MNKD.pdf
OvaScience Inc.
OvaScience Inc.'s stock declined 40.98% to close Tuesday's
session at USD 8.57. The share price
vacillated between USD 8.35 and USD
10.68 marking a new 52-week low during the session. The
stock recorded a trading volume of 3.83 million shares, which was
above its 50-day daily average volume of 0.76 million shares and
above its 52-week average volume of 0.62 million shares. Over the
last three days OvaScience Inc.'s shares have declined by 52.52%
and in the past one week the stock has moved down 54.41%. Moreover,
in the last six months the stock has lost 75.32% and year to date
the shares have shed 80.62%. On a compounded total return basis,
the company has shown a negative return of 48.37% in the past one
year. The complimentary notes on OVA Scan be downloaded in PDF
format at: http://www.aciassociation.com/OVAS.pdf
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein. The information in this release has been sourced
from a third party data base.
NO WARRANTY
ACI Association, the Author, the Reviewer and the Sponsor
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com